Literature DB >> 16530087

An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer.

Zhengkui Sun1, Zhenxiang Yao, Shengchun Liu, Hua Tang, Xiong Yan.   

Abstract

Tumor-associated macrophages (TAMs) have the potential to induce both immune activation and immune tolerance. Recent studies have indicated that in breast cancers the pro-tumor role of TAMs is dominant. We induced rat peritoneal macrophages with rat breast cancer cell-conditioned medium and analyzed signal transducer and activators of transcription 3 (Stat3) activities of the cells. Then these cells were transfected with Stat3 decoy oligonucleotides (ODNs) and were stimulated by lipopolysaccharide (LPS). The results demonstrate that induced macrophages displayed a reduction of cytotoxicity and antigen-presenting function in comparison with control but transfection with Stat3 decoy ODNs enhanced cytotoxicity and antigen-presenting function of the macrophages. Furthermore, injection of induced macrophages promoted tumor growth accompanied by immunosuppression in the rat tumor models, but injection of induced macrophages transfected with Stat3 decoy ODNs led to retarded tumor growth accompanied by immune activation. The data suggest that immunosuppressive activities of TAMs correlate with over-activated Stat3 signaling of the cells and disruption of Stat3 activity of TAMs can enhance rat immune response to breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16530087     DOI: 10.1016/j.imbio.2005.11.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  21 in total

Review 1.  Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.

Authors:  Johan Kreuger; Mia Phillipson
Journal:  Nat Rev Drug Discov       Date:  2015-11-27       Impact factor: 84.694

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

3.  STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.

Authors:  Daniel Kogan; Alexander Grabner; Christopher Yanucil; Christian Faul; Vijay Kumar Ulaganathan
Journal:  J Clin Invest       Date:  2018-04-03       Impact factor: 14.808

4.  Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

Authors:  Malabika Sen; Sonali Joyce; Mary Panahandeh; Changyou Li; Sufi M Thomas; Jessica Maxwell; Lin Wang; William E Gooding; Daniel E Johnson; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

5.  Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.

Authors:  Malabika Sen; Kathleen Paul; Maria L Freilino; Hua Li; Changyou Li; Daniel E Johnson; Lin Wang; Julie Eiseman; Jennifer R Grandis
Journal:  Mol Med       Date:  2014-03-18       Impact factor: 6.354

Review 6.  Innate immune cells in breast cancer--from villains to heroes?

Authors:  Tim Kees; Mikala Egeblad
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-07-26       Impact factor: 2.673

7.  Primed innate immunity leads to autoinflammatory disease in PSTPIP2-deficient cmo mice.

Authors:  Violeta Chitu; Polly J Ferguson; Rosalie de Bruijn; Annette J Schlueter; Luis A Ochoa; Thomas J Waldschmidt; Yee-Guide Yeung; E Richard Stanley
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

8.  Lack of toxicity of a STAT3 decoy oligonucleotide.

Authors:  Malabika Sen; Patricia J Tosca; Christa Zwayer; Michael J Ryan; Jerry D Johnson; Katherine A B Knostman; Patricia C Giclas; James O Peggins; Joseph E Tomaszewski; Timothy P McMurray; Changyou Li; Michael S Leibowitz; Robert L Ferris; William E Gooding; Sufi M Thomas; Daniel E Johnson; Jennifer R Grandis
Journal:  Cancer Chemother Pharmacol       Date:  2008-09-03       Impact factor: 3.333

9.  Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.

Authors:  Changyou Li; Yan Zang; Malabika Sen; Rebecca J Leeman-Neill; David S K Man; Jennifer R Grandis; Daniel E Johnson
Journal:  Mol Cancer Ther       Date:  2009-07-28       Impact factor: 6.261

10.  CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.

Authors:  Vinit Kumar; Pingyan Cheng; Thomas Condamine; Sridevi Mony; Lucia R Languino; Judith C McCaffrey; Neil Hockstein; Michael Guarino; Gregory Masters; Emily Penman; Fred Denstman; Xiaowei Xu; Dario C Altieri; Hong Du; Cong Yan; Dmitry I Gabrilovich
Journal:  Immunity       Date:  2016-02-16       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.